CN115624506A - Oral care product containing inulin and application thereof - Google Patents
Oral care product containing inulin and application thereof Download PDFInfo
- Publication number
- CN115624506A CN115624506A CN202110810685.6A CN202110810685A CN115624506A CN 115624506 A CN115624506 A CN 115624506A CN 202110810685 A CN202110810685 A CN 202110810685A CN 115624506 A CN115624506 A CN 115624506A
- Authority
- CN
- China
- Prior art keywords
- oral care
- inulin
- care composition
- maltose
- film according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 title claims abstract description 104
- 229920001202 Inulin Polymers 0.000 title claims abstract description 103
- 229940029339 inulin Drugs 0.000 title claims abstract description 103
- 239000000203 mixture Substances 0.000 claims abstract description 87
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims abstract description 39
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims abstract description 39
- 241000894006 Bacteria Species 0.000 claims abstract description 24
- 230000009286 beneficial effect Effects 0.000 claims abstract description 16
- 150000003751 zinc Chemical class 0.000 claims description 27
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims description 19
- 239000011746 zinc citrate Substances 0.000 claims description 19
- 235000006076 zinc citrate Nutrition 0.000 claims description 19
- 229940068475 zinc citrate Drugs 0.000 claims description 19
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 10
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 9
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 9
- 239000000811 xylitol Substances 0.000 claims description 9
- 235000010447 xylitol Nutrition 0.000 claims description 9
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 9
- 229960002675 xylitol Drugs 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 6
- ONDPHDOFVYQSGI-UHFFFAOYSA-N zinc nitrate Chemical compound [Zn+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ONDPHDOFVYQSGI-UHFFFAOYSA-N 0.000 claims description 6
- 229940034610 toothpaste Drugs 0.000 claims description 5
- 239000000606 toothpaste Substances 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 4
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000002324 mouth wash Substances 0.000 claims description 3
- 229940051866 mouthwash Drugs 0.000 claims description 3
- 239000011592 zinc chloride Substances 0.000 claims description 3
- 235000005074 zinc chloride Nutrition 0.000 claims description 3
- 239000011670 zinc gluconate Substances 0.000 claims description 3
- 235000011478 zinc gluconate Nutrition 0.000 claims description 3
- 229960000306 zinc gluconate Drugs 0.000 claims description 3
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 3
- 229960001763 zinc sulfate Drugs 0.000 claims description 3
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 3
- 230000000052 comparative effect Effects 0.000 description 26
- 239000000243 solution Substances 0.000 description 26
- 230000009467 reduction Effects 0.000 description 19
- 238000010521 absorption reaction Methods 0.000 description 15
- 210000000214 mouth Anatomy 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 10
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 229930091371 Fructose Natural products 0.000 description 8
- 239000005715 Fructose Substances 0.000 description 8
- 244000052616 bacterial pathogen Species 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 206010006326 Breath odour Diseases 0.000 description 5
- 208000032139 Halitosis Diseases 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 239000004075 cariostatic agent Substances 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 239000003906 humectant Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 229920002670 Fructan Polymers 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 239000007844 bleaching agent Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- -1 zinc salt Chemical class 0.000 description 4
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 3
- 241000605986 Fusobacterium nucleatum Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 241000194023 Streptococcus sanguinis Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000002925 dental caries Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- LBTVHXHERHESKG-UHFFFAOYSA-N tetrahydrocurcumin Chemical compound C1=C(O)C(OC)=CC(CCC(=O)CC(=O)CCC=2C=C(OC)C(O)=CC=2)=C1 LBTVHXHERHESKG-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000605894 Porphyromonas Species 0.000 description 1
- 241000605862 Porphyromonas gingivalis Species 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 241001135261 Prevotella oralis Species 0.000 description 1
- 101710184309 Probable sucrose-6-phosphate hydrolase Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 241000194024 Streptococcus salivarius Species 0.000 description 1
- 102400000472 Sucrase Human genes 0.000 description 1
- 101710112652 Sucrose-6-phosphate hydrolase Proteins 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 241001148135 Veillonella parvula Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000000675 anti-caries Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000001479 atomic absorption spectroscopy Methods 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- NFZRUYPJVCITCX-UHFFFAOYSA-L calcium;hydrogen phosphate;2-hydroxypropanoic acid Chemical compound [Ca+2].OP([O-])([O-])=O.CC(O)C(O)=O NFZRUYPJVCITCX-UHFFFAOYSA-L 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 239000003975 dentin desensitizing agent Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004993 emission spectroscopy Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000009616 inductively coupled plasma Methods 0.000 description 1
- 230000002701 inhibitory effect on caries Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000011742 magnesium glycerophosphate Substances 0.000 description 1
- 235000001130 magnesium glycerophosphate Nutrition 0.000 description 1
- BHJKUVVFSKEBEX-UHFFFAOYSA-L magnesium;2,3-dihydroxypropyl phosphate Chemical compound [Mg+2].OCC(O)COP([O-])([O-])=O BHJKUVVFSKEBEX-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229940023486 oral product Drugs 0.000 description 1
- 239000013588 oral product Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940005657 pyrophosphoric acid Drugs 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- VSJRDSLPNMGNFG-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate;trihydrate Chemical compound O.O.O.[Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O VSJRDSLPNMGNFG-UHFFFAOYSA-H 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940085658 zinc citrate trihydrate Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cosmetics (AREA)
Abstract
The present invention provides an oral care composition comprising inulin and uses thereof, the composition comprising: 1) Inulin; 2) An orally acceptable carrier; wherein the inulin contains maltose, and the mass ratio of maltose in the inulin is 0.05-1%; the weight percentage of the oral care composition is 0.1-30%. The oral care composition can better absorb breath, and can regulate flora, inhibit growth of harmful bacteria in the flora, and promote growth of beneficial bacteria.
Description
Technical Field
The invention relates to the technical field of oral care, in particular to an oral care product containing inulin and application thereof.
Background
The oral micro-ecology is one of four micro-ecological systems of human body, and the complexity is second to intestinal micro-ecological system. The human oral micro-ecosystem contains more than 700 microorganisms, wherein part of pathogenic bacteria are responsible for oral diseases, such as dental caries caused by streptococcus mutans, and breath caused by porphyromonas and fusobacterium nucleatum. In the prior art, an antibacterial agent is usually adopted to inhibit the growth of pathogenic bacteria to prevent caries or remove halitosis, or active ingredients are directly added to absorb halitosis, or prebiotics/probiotics are added to promote the growth of beneficial or neutral bacteria such as streptococcus salivarius and streptococcus sanguis to balance oral flora, so that the oral micro-ecological environment is indirectly improved.
Disclosure of Invention
The first technical problem to be solved by the present invention is to provide an oral care composition comprising inulin. The oral care composition can better absorb breath, and can regulate flora, inhibit growth of harmful bacteria in the flora, and promote growth of beneficial bacteria. In the present application, when the inulin contains maltose in an amount of 0.1-1% by mass and inulin in an amount of 0.1-30% by mass in the oral care composition, the oral care composition can absorb H in an amount of 45% or more 2 S; especially, when the inulin contains maltose 0.39-1 wt% and inulin 5-30 wt%, the oral care composition can absorb H more than or equal to 90% 2 S。
The second technical problem to be solved by the present invention is to provide the use of the above oral care composition for absorbing breath.
The third technical problem to be solved by the invention is to provide the application of the oral care composition in inhibiting the growth of harmful bacteria in the oral cavity and promoting the growth of beneficial bacteria in the oral cavity.
In order to solve the first technical problem, the invention adopts the following technical scheme:
an oral care composition comprising a film, comprising:
1) Inulin;
2) An orally acceptable carrier;
wherein the inulin contains maltose, and the mass ratio of the maltose in the inulin is 0.05-1%;
the inulin accounts for 0.1-30% of the oral care composition by mass.
In certain preferred embodiments, the maltose comprises 0.1-1% by mass of the inulin.
In certain more preferred embodiments, the maltose comprises 0.39-1% by mass of the inulin.
In certain more preferred embodiments, the inulin is present in the oral care composition in an amount of from 5 to 30% by weight.
In the present application, when the inulin contains maltose in an amount of 0.1-1% by mass and inulin in an amount of 0.1-30% by mass in the oral care composition, the oral care composition can absorb H in an amount of 45% or more 2 S; especially, when the inulin contains maltose 0.39-1 wt% and inulin 5-30 wt%, the oral care composition can absorb H more than or equal to 90% 2 S
In certain preferred embodiments, the oral care product further comprises a soluble zinc salt;
in certain preferred embodiments, the soluble zinc salt is derived from one or a combination of more than one of zinc citrate, zinc sulfate, zinc nitrate, zinc chloride, zinc gluconate.
In certain preferred embodiments, the soluble zinc salt is zinc citrate;
in certain preferred embodiments, the soluble zinc salt is present in the composition at a level of from 0.01 to 2.2% by weight;
in certain preferred embodiments, the inulin: the mass ratio of the soluble zinc salt is 25-1:4;
in certain preferred embodiments, the inulin: the mass ratio of the soluble zinc salt is 10-5:8;
in certain preferred embodiments, the oral care composition further comprises lactobacillus paracasei;
in certain preferred embodiments, the oral care composition further comprises xylitol;
in certain preferred embodiments, the oral product comprises a mouthwash or a liquid toothpaste.
A second technical problem to be solved by the present invention is to provide the use of the above oral care composition for absorbing breath.
The third technical problem to be solved by the invention is to provide the application of the oral care composition in inhibiting the growth of harmful bacteria in the oral cavity and promoting the growth of beneficial bacteria in the oral cavity.
The starting materials of the present invention are commercially available, unless otherwise specified, and the equipment used in the present invention may be any equipment conventionally used in the art or may be any equipment known in the art.
The invention has the advantages of
Compared with the prior art, the oral care composition containing inulin can better absorb breath, regulate flora, inhibit the growth of harmful bacteria in the flora and promote the growth of beneficial bacteria. In the present application, when the inulin contains maltose in an amount of 0.1-1% by mass and the inulin is contained in an amount of 0.1-30% by mass in the oral care composition, the oral care composition can absorb H in an amount of 45% or more 2 S; especially, when the inulin contains maltose 0.39-1 wt%, and inulin is 5-30 wt% in the oral care composition, the oral care composition can absorb H more than or equal to 90% 2 S。
Drawings
FIG. 1 is a bar graph comparing the efficacy of balanced microflora of the present invention.
Detailed Description
In order to more clearly illustrate the invention, the invention is further described below in connection with preferred embodiments. It is to be understood by persons skilled in the art that the following detailed description is illustrative and not restrictive, and is not to be taken as limiting the scope of the invention.
All percentages and ratios used herein are by weight of the total composition, unless otherwise specified. Unless otherwise indicated, all percentages, ratios, and levels of ingredients referred to herein are based on the actual amount of the ingredient, and do not include solvents, fillers, or other materials found in commercially available products with which the ingredient may be combined.
The term "comprising" as used herein means that other steps and ingredients which do not affect the end result can be added.
The term "preferably" and its variants herein refer to embodiments of the invention that are capable of providing specific benefits under specific circumstances. However, other embodiments may also be preferred under the same or other circumstances. Furthermore, the detailed description of one or more preferred embodiments does not imply that other embodiments are not useful, and is not intended to exclude other embodiments from the scope of the invention.
The method is carried out according to conventional conditions or conditions suggested by manufacturers if specific conditions are not indicated in the embodiment of the invention; the reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
As one aspect of the present invention, an oral care composition comprising inulin, comprising:
1) Inulin;
2) An orally acceptable carrier;
wherein the inulin contains maltose, and the mass ratio of the maltose in the inulin is 0.05-1%;
the inulin accounts for 0.1-30% of the oral care composition by mass.
Inulin powder
Inulin is a natural fructan mixture formed by connecting D-fructofuranose molecules by beta- (2,1) glycosidic bonds, and connecting the tail end of each inulin molecule by alpha- (1,2) glycosidic bonds to form a glucose residue, and the polymerization Degree (DP) is 2-60. Inulin is a soluble dietary fiber, and can be hardly hydrolyzed and digested by gastric acid and can be utilized only by beneficial microorganisms in colon, so that the flora environment in intestinal tract can be improved, and the intestinal tract environment is further improved, so that inulin is frequently used as a probiotic source in the prior art. The prior art also reports that the inulin has growth promoting effect on oral nonpathogenic bacteria and has the function of absorbing oral odor.
The invention has surprisingly found that when inulin contains a certain proportion of maltose, the oral care composition containing the inulin can better inhibit breath, regulate flora, inhibit the growth of harmful bacteria in the flora, and promote the growth of beneficial bacteria.
In certain embodiments of the invention, the inulin comprises maltose, and the mass ratio of maltose in the inulin is 0.05-1%, such as, but not limited to, 0.05-0.90%,0.05-0.80%,0.05-0.70%,0.05-0.60%,0.05-0.50%,0.05-0.40%,0.05-0.30%,0.05-0.20%,0.05-0.10%,0.1-1%,0.1-0.90%,0.1-0.80%,0.1-0.70%,0.1-0.60%,0.1-0.50%,0.1-0.40%,0.1-0.30%,0.1-0.20%,0.2-1%,0.2-0.90%,0.2-0.80%,0.2-0.70%,0.2-0.60%,0.2-0.50%,0.2-0.40%,0.2-0.30%,0.3-1%,0.3-0.90%,0.3-0.80%,0.3-0.70%,0.3-0.60%,0.3-0.50%,0.3-0.40%,0.39-1%,0.4-0.90%,0.4-0.80%,0.4-0.70%,0.4-0.60%,0.4-0.50%,0.5-1%,0.5-0.9%,0.5-0.8%,0.5-0.7%,0.5-0.6%.
In certain embodiments of the invention, the inulin is present in the oral care composition in a mass ratio of 0.1-30%, such as, but not limited to, 0.1-25%,0.1-20%,0.1-15%,0.1-10%,0.1-5%,1-30%,5-30%,10-30%,15-30%,20-30%,0.1-4.5%,0.1-4%,0.1-3.5%,0.1-3%,0.1-2.5%,0.1-2%,0.1-1.5%,0.1-1%,0.1-0.5%,0.3-5%,0.3-4.5%,0.3-4%,0.3-3.5%,0.3-3%,0.3-2.5%, 0.3-1.5%,0.3-1%,0.3-0.5%,0.4-30%,0.5-5%,0.5-4.5%,0.5-4%,0.5-3.5%,0.5-3%,0.5-2.5%,0.5-2%,0.5-1.5%,0.5-1%,1-5%,1-4.5%,1-4%,1-3.5%,1-3%,1-2.5%,1-2%,1-1.5%,1.5-5%,1.5-4.5%, 1.5-3.5%,1.5-3%,1.5-2.5%,1.5-2%,1-1.5%,2-5%,2-4.5%, 2-3.5%,2-3%,2-2.5%,25-5%,2.5-4.5%, 2-3.5%, 2-5-3.5%, 2.5-5%, 2.5-4.5%, 2-5-3.5%, 2.5-4.5%, 2-5%, 3-4.5%,3-4% and 3-3.5%.
In certain embodiments of the present invention, wherein the inulin is detected by the following method:
1. extracting fructan: accurately weighing 1.0 toothpaste sample, adding 8088 ℃ distilled water, stirring, keeping the temperature at 80 ℃ for 158in until the sample is uniformly dispersed; the mixture was cooled to room temperature, quantitatively transferred to a 10088 volumetric flask, the volume was determined with deionized water, shaken up and filtered, and the filtrate was collected.
2. Removal of sucrose, starch and reducing sugars:
2.1 taking 0.288 of the filtrate to the bottom of a glass test tube, adding 0.288 of a sucrase/amylase solution and heating to 40 ℃ for 38in
2.2 adding the newly prepared alkaline borohydride solution, and stirring for 308 inches at 40 ℃ to degrade the reducing sugar into sugar alcohol.
2.3 Add 0.588 of acetic acid and vortex to remove excess borohydride, with constant bubbling noted. The sample after the reaction was solution A.
3. Hydrolysis and measurement of fructan:
3.1 taking 0.288 solution A to the bottom of the test tube, adding 0.188 fructosyl enzyme solution, shaking uniformly on a vortex oscillator, and hydrolyzing levan into fructose and glucose at constant temperature of 40 ℃ in 208 in.
3.2 Add 5.088PAHBAH solution, put in a precise boiling water bath for 68in, then immediately put in cold water (18-22 ℃) to cool for 58in
3.3 immediately, the absorbance of the solution at 410n8 was measured.
And parallelly testing the fructose standard solution, the blank reagent and the absorbance of the sucrose control sample, deducting the blank and the control, and comparing with the standard solution to obtain the fructan content.
In the invention, the content of maltose can be detected by a detection method of national standard GB 5009.8-2016.
Soluble zinc salt
By "soluble zinc salt" is meant herein: zinc salts which can be present in a solvent (e.g. water) or matrix (e.g. toothpaste) without being in the form of a precipitate are to be distinguished from zinc salts which are present in an insoluble form, such as solid zinc oxide. Soluble zinc salts may include zinc salts that, when dispersed in a solvent or matrix, exist in ionic form, in complex, chelate form, and in dispersible combinations, such as, but not limited to, one or a combination of more than one of zinc citrate, zinc citrate trihydrate, zinc sulfate, zinc nitrate, zinc chloride, zinc gluconate.
Soluble zinc salts are commonly used in the oral care field to absorb breath and inhibit bacterial growth, but soluble zinc salts do not distinguish between harmful and beneficial bacteria when bacteriostatic. The invention unexpectedly discovers that when inulin containing maltose and a soluble zinc salt are combined, the inulin and the soluble zinc salt have the function of synergistically absorbing breath, and after the inulin and the soluble zinc salt are applied to the oral cavity, the proportion of beneficial bacteria in the oral cavity flora is increased, and the proportion of pathogenic bacteria is reduced.
In certain embodiments of the present invention, the soluble zinc salt may be measured in soluble zinc concentration by methods known to those skilled in the art, such as atomic absorption spectroscopy, inductively coupled plasma emission spectroscopy, and the like.
In certain embodiments of the invention, the inulin: the mass ratio of the soluble zinc salt is 25: the following, 12:1-4:4, 10:1-4:4,8:1-4:4,5:1-4:4,3:1-4:4,1:1-4:4,1:1.5-4:4,1:2-4:4,1:2.5-4:4,1:3-4:4.
In certain embodiments of the present invention, the soluble zinc salt is present in the oral care composition in a mass ratio of 0.01 to 5%, such as, but not limited to, 0.05 to 5%,0.1 to 5%,0.5 to 5%,1 to 5%,2 to 5%,3 to 5%,0.1 to 4.5%,0.1 to 4%,0.1 to 3.5%,0.1 to 3%,0.1 to 2.5%,0.1 to 2%,0.1 to 1.5%,0.1 to 1%,0.1 to 0.5%,0.3 to 4.5%,0.3 to 4%,0.3 to 3.5%,0.3 to 3%,0.3 to 2.5%,0.3 to 2%,0.3 to 1.5%,0.3-1%,0.3-0.5%,0.5-4.5%,0.5-4%,0.5-3.5%,0.5-3%,0.5-2.5%,0.5-2%,0.5-1.5%,0.5-1%,1-4.5%,1-4%,1-3.5%,1-3%,1-2.5%,1-2%,1-1.5%,1.5-4.5%,1.5-4%,1.5-3.5%,1.5-3%,1.5-2.5%,1.5-2%,1-1.5%,2-4.5%,2-4%,2-3.5%, 2-2.5%,2.5-4.5%,2.5-4%,2.5-3.5%, 3-4.5%, 3-3.5%.
Xylitol, its preparation method and use
The invention unexpectedly discovers that when xylitol is further added into the oral care composition, the effect of absorbing halitosis is obviously improved, and after the oral care composition is applied to the oral cavity, the proportion of beneficial bacteria in oral flora is increased, and the proportion of pathogenic bacteria is reduced.
The present inventors have surprisingly found that when xylitol is further added to an oral care composition comprising inulin (containing maltose) and a soluble zinc salt, the efficacy of oral gas absorption is further improved and after application to the oral cavity, the proportion of beneficial bacteria in the oral flora is further increased and the proportion of pathogenic bacteria is further decreased.
In certain embodiments of the invention, the mass ratio of xylitol in the oral care product formulation is 0.01 to 10%, such as, but not limited to, 0.05 to 8%,0.05 to 5%,0.1 to 5%,0.5 to 5%,1 to 5%,2 to 5%,3 to 5%,0.1 to 4.5%,0.1 to 4%,0.1 to 3.5%,0.1 to 3%,0.1 to 2.5%,0.1 to 2%,0.1 to 1.5%,0.1 to 1%,0.1 to 0.5%,0.3 to 4.5%,0.3 to 4%,0.3 to 3.5%,0.3 to 3%,0.3 to 2.5%,0.3 to 2%,0.3 to 1.5%,0.3-1%,0.3-0.5%,0.5-4.5%,0.5-4%,0.5-3.5%,0.5-3%,0.5-2.5%,0.5-2%,0.5-1.5%,0.5-1%,1-4.5%,1-4%,1-3.5%,1-3%,1-2.5%,1-2%,1-1.5%,1.5-4.5%,1.5-4%,1.5-3.5%,1.5-3%,1.5-2.5%,1.5-2%,1-1.5%,2-4.5%,2-4%,2-3.5%,2-3%,2-2.5%,2.5-4.5%,2.5-4%,2.5-3.5%,2.5-3%,3-4.5%,3-4%,3-3.5%.
Lactobacillus paracasei
The oral care composition is unexpectedly found to have obviously improved breath absorption effect when lactobacillus paracasei is further added, and after the oral care composition is applied to the oral cavity, the proportion of beneficial bacteria in oral flora is increased, and the proportion of pathogenic bacteria is reduced.
The present inventors have surprisingly found that when lactobacillus paracasei is further added to an oral care composition comprising inulin (containing maltose) and a soluble zinc salt, the efficacy of oral gas absorption is further improved, and after application to the oral cavity, the proportion of beneficial bacteria in the oral flora is further increased and the proportion of pathogenic bacteria is further decreased.
In certain embodiments of the invention, the strain of Lactobacillus paracasei is ADP-1.
In certain embodiments of the invention, the mass ratio of the lactobacillus paracasei in the oral care product formulation is 0.01 to 10%, such as, but not limited to, 0.05 to 8%,0.05 to 5%,0.1 to 5%,0.5 to 5%,1 to 5%,2 to 5%,3 to 5%,0.1 to 4.5%,0.1 to 4%,0.1 to 3.5%,0.1 to 3%,0.1 to 2.5%,0.1 to 2%,0.1 to 1.5%,0.1 to 1%,0.1 to 0.5%,0.3 to 4.5%,0.3 to 4%,0.3 to 3.5%,0.3 to 2.5%,0.3 to 2%,0.3 to 1.5%,0.3 to 1%,0.3 to 0.5%,0.5 to 4.5%,0.5 to 4%,0.5-3.5%,0.5-3%,0.5-2.5%,0.5-2%,0.5-1.5%,0.5-1%,1-4.5%,1-4%,1-3.5%,1-3%,1-2.5%,1-2%,1-1.5%,1.5-4.5%,1.5-4%,1.5-3.5%,1.5-3%,1.5-2.5%,1.5-2%,1-1.5%,2-4.5%,2-4%,2-3.5%, 2-2.5%,2.5-4.5%,2.5-4%,2.5-3.5%, 3-4.5%,3-4%,3-3.5%,0.05-0.90%,0.05-0.80%,0.05-0.70%, 0.05-0.05%, 0.50-30%, 0.05-0.5%, 0.5-4%, 1.5%, 1-4.5%, 2-3%, 2.5%, 0.05-0.20%,0.05-0.10%,0.1-1%,0.1-0.90%,0.1-0.80%,0.1-0.70%,0.1-0.60%,0.1-0.50%,0.1-0.40%,0.1-0.30%,0.1-0.20%,0.2-1%,0.2-0.90%,0.2-0.80%,0.2-0.70%,0.2-0.60%,0.2-0.50%,0.2-0.40%,0.2-0.30%,0.3-1%,0.3-0.90%,0.3-0.80%,0.3-0.70%,0.3-0.60%,0.3-0.50%,0.3-0.40%,0.4-1%,0.4-0.90%,0.4-0.80%,0.4-0.70%, 0.4-0.50%.
Other orally acceptable carriers
In certain embodiments of the present invention, the oral care composition is a liquid toothpaste or mouthwash.
In the present invention, the "orally acceptable carrier" refers to any vehicle suitable for formulating the oral care compositions disclosed herein; (ii) is not harmful to the mammal when the orally acceptable carrier is retained in the mouth in the amounts disclosed herein without swallowing for a period of time sufficient to allow effective contact with the tooth surface as required by the present invention; overall, an orally acceptable carrier is not harmful if not intentionally swallowed; suitable orally acceptable carriers include, for example, one or more of the following: water, thickeners, pH adjusters, humectants, sweeteners, flavorants, visual aids (e.g., colors, dyes, or mixtures thereof), anti-caries agents, antibacterial agents, whitening agents, desensitizing agents, vitamins, preservatives, enzymes, mixtures thereof, and the like.
In certain preferred embodiments of the present invention, adjuvants such as humectants and/or thickeners are included in the oral care composition.
"humectants" are ingredients that prevent the oral care composition from becoming dehydrated and hardened. Exemplary humectants include, but are not limited to, glycerin, propylene glycol, sorbitol, and the like. The humectant is typically present in the oral care composition in an amount of 10 to 80% by mass.
"pH modifying agents" can substantially modify the pH value of an oral care product formulation. Exemplary pH adjusters include, but are not limited to, one or more of sodium hydroxide, hydrochloric acid, sulfuric acid, citric acid and salts thereof, lactic acid and salts thereof, phosphoric acid and salts thereof, phthalic acid and salts thereof, pyrophosphoric acid and salts thereof, tripolyphosphoric acid and salts thereof, polyphosphoric acid and salts thereof, and acetic acid and salts thereof.
According to certain embodiments of the present application, active ingredients such as antibacterial agents, anticaries agents, anti-sensitivity agents, and/or whitening agents may be further included in the oral care compositions.
By "antibacterial agent" is meant a chemical substance that is capable of maintaining the growth or reproduction of certain microorganisms in an oral care composition below a necessary level over a period of time. Exemplary antimicrobial agents include, but are not limited to: tetrahydrocurcumin, cetylpyridinium chloride, triclosan, and the like.
"anticaries agent" means a substance having an inhibitory effect on caries, for example, a substance which enhances the anticaries ability of teeth by decreasing the solubility of enamel hydroxyapatite, or a substance which controls plaque, inhibiting bacterial growth. Exemplary anticaries agents include, but are not limited to, phosphorus-containing agents (calcium phosphate, magnesium glycerophosphate, calcium lactate phosphate, sodium caseinate, etc.), or arginine and its derivatives. Preferably, in certain embodiments, the anticaries agent comprises a fluoride ion source.
An "anti-sensitivity agent" refers to a substance that prevents or treats dentinal hypersensitivity by inhibiting nerve impulses or being capable of closing or decreasing the permeability of dentinal tubules. Exemplary anti-sensitivity agents include, but are not limited to: potassium ion sources such as dipotassium glycyrrhizinate, potassium fluoride, potassium nitrate, potassium chloride and the like.
The "whitening agent" refers to a substance having a whitening effect on teeth. Exemplary whitening agents include, but are not limited to: a peroxide bleaching agent.
Evaluation method for breath absorption efficacy
This experiment was performed by inhibiting salivary bacteria from producing H 2 S to evaluate the ability of the composition to absorb breath
1. TSB medium solution (0.3% (v/v) and cysteine (0.1%) were prepared, sterilized at 121 ℃ for 208in, and cooled to room temperature.
2. Adding reagents according to the following sequence and proportion: TSB, cysteine, saliva, inulin solutions of various concentrations.
Wherein the blank group is not added with inulin solution, and is added with 288 sterile water
3. And covering the sealing bottle with a rubber pad and a cover, and sealing.
4. And (3) removing seals at two ends of the hydrogen sulfide absorption tube, inserting the hydrogen sulfide absorption tube into the sealed bottle in the step (3), and putting the sealed bottle into a carbon dioxide incubator for culture at 37 ℃.
5. And 4, after 0h and 24h are carried out in the step 4, observing the change of the hydrogen sulfide absorption tube, and photographing and recording.
6. Calculate H 2 Reduction rate of S
Raw materials of No. 1-7 inulin
Table 1 shows the data of the measurement of the total sugar content in 7 different inulin raw materials.
Table 1: (the percentages in the table are by weight)
| 2# | 3# | 5# | 1# | 4# | 7# | 6# | |
| Maltose | 0.1％ | 0.39％ | 1％ | 0.05％ | / | / | / |
| Fructose | / | / | / | / | 0.4％ | 1.68％ | 3.47％ |
| Glucose | / | / | / | / | / | 0.33％ | / |
| Sucrose | / | / | / | / | / | / | 0.83％ |
That is to say that the position of the first electrode,
Examples 1 to 3, comparative examples 1 to 4
Solutions with inulin concentrations of # 1-7 of 0.5wt% were prepared according to Table 2,
TABLE 2 (percentages in the table are by weight)
The efficacy of the formulations of examples 1 to 3 and comparative examples 1 to 4 for inhibiting halitosis was examined according to the evaluation method for breath absorption efficacy described above. The test results are shown in the following table 3:
TABLE 3
| Example 1 | Examples2 | Example 3 | Comparative example 1 | Comparative example 2 | Comparative example 3 | Comparative example 4 | |
| H 2 Rate of S reduction | 45％ | 59％ | 62％ | 16％ | 11％ | 29％ | 33％ |
When the concentration of inulin in the oral care composition is 0.5wt%, it can be seen in combination of tables 2 and 3:
comparative example 1 inulin starting material contained 0.05% maltose and the solution absorbed only 16% of the H 2 S；
Example 1 the mass fraction of maltose in the inulin raw material was increased to 0.1%, at which point the solution absorbed 45% of H 2 S, absorption of H 2 The capability of S is remarkably improved;
example 2 the mass proportion of maltose in the inulin raw material was further increased to 0.39%, at which time the solution absorbed 59% of H 2 S；
Example 3 maltose content in inulin raw material reached 1.0% by mass, at which point the solution absorbed 62% of H 2 S；
Comparative example 2 the inulin raw material contained 0.4% fructose, the mass ratio of free sugar in the inulin raw material was equivalent to that of maltose in example 2, but the solution absorbed only 11% of H 2 S; comparative example 3 inulin starting material contained 1.68% fructose and 0.33% glucose, the total amount of free sugars being much greater than the maltose of example 2 in inulinIn proportion, but the solution only absorbed 29% of H 2 S; comparative example 4 inulin raw material containing 3.47% and 0.83% sucrose, the mass ratio of the total amount of free sugars was much greater than that of maltose in example 2, but the solution absorbed only 51% of H 2 S；
Examples 4 to 9
Oral care compositions were formulated as in Table 4 as examples 4-9 and examples 4-9 were tested for H absorption 2 (ii) the ability of S; for convenience, the data from example 2 are also presented in the table.
TABLE 4 (percentages in the table are by weight)
As can be seen from table 4:
example 2 is an aqueous solution containing 0.5% of 3# inulin (containing 0.39% by mass of maltose), and 59% of H was absorbed 2 S；
Example 4 is an aqueous solution containing 0.2% zinc citrate, absorbing 57% of H 2 S, the function of absorbing the breath is equivalent to that of the example 2;
example 5 is an aqueous solution containing 0.45% 3# inulin (inulin concentration 90% of example 2) and 0.02% zinc citrate (zinc citrate concentration 10% of example 4), when the mass ratio of inulin to zinc citrate in the solution is 45, the solution having absorbed 64% H 2 S, example 5 absorbs H compared to examples 2 and 4 2 The capability of S is greatly increased;
example 6 is an aqueous solution containing 0.4% of 3# inulin (inulin concentration 80% of example 2) and 0.02% of zinc citrate (zinc citrate concentration 20% of example 4), absorbing 70% of H 2 S, example 6 absorbs H compared to examples 2 and 4 2 The capability of S is remarkably increased;
example 7 is an aqueous solution containing 0.25%3# inulin (inulin concentration 50% of example 2) and 0.1% zinc citrate (zinc citrate concentration 50% of example 4), absorbing72% of H 2 S, example 7 absorbs H compared to examples 2 and 4 2 The capability of S is remarkably increased;
example 8 was an aqueous solution containing 0.1%3# inulin (inulin concentration 20% of example 2) and 0.16% zinc citrate (zinc citrate concentration 80% of example 4), absorbing 69% of H 2 S, example 8 absorbs H compared to examples 2 and 4 2 The capability of S is remarkably increased;
example 9 was an aqueous solution containing 0.05%3# inulin (inulin concentration 10% of example 2) and 0.18% zinc citrate (zinc citrate concentration 90% of example 4), absorbing 62% of H 2 S, example 9 absorbs H compared to examples 2 and 4 2 The capability of S is greatly increased;
comparative examples 5 to 7
Oral care compositions were formulated according to the formulation of Table 5 as comparative examples 5-7, example 7 being set forth in Table 5 for ease of comparison, comparative examples 5-7 being tested for H absorption 2 Ability of S
TABLE 5 (percentages in the table are by weight)
As can be seen from table 5: example 7 and comparative examples 5 to 7 were each an aqueous solution having an inulin concentration of 0.25% and a zinc citrate concentration of 0.1%, wherein example 7 added 3# inulin, H 2 The S reduction rate is 72%; comparative example 5 addition of No. 4 inulin, H 2 The S reduction rate is 25%; comparative example 6 addition of 7# inulin, H 2 The S reduction rate is 50%; comparative example 7 addition of No. 6 inulin, H 2 The S reduction rate is 52%; compared with comparative examples 5-7, solution H containing maltose-containing inulin and zinc citrate was added 2 The S absorption capacity is obviously improved.
Comparative example 8, examples 10 to 11
Oral care compositions were formulated as in Table 6, comparative example 8 and examples 10-11, and for comparison, the data of example 2 and example 5 are set forth in Table 6, comparative example 8 and example 1 were tested0-11 absorption of H 2 The ability of S.
TABLE 6 (percentages in the table are by weight)
As can be seen from table 6:
comparative example 8 is a 2% strength aqueous solution of xylitol, H 2 The S reduction rate is only 4%;
example 10 the addition of 2% by mass of xylitol to example 2, the ability of the solution to absorb breath was determined as 59% 2 S reduction rate is increased to 70% 2 (ii) a rate of S reduction;
example 11 is prepared by adding 2% by mass of xylitol to example 5, and then, the solution has an ability to absorb saliva 64% 2 S reduction rate is increased to 80% 2 The S reduction rate and the increase are larger than those of the embodiment 10.
Comparative example 9, examples 12 to 13
Oral care compositions were formulated according to the formulation of Table 7 as comparative example 9 and examples 12-13, example 2 and example 5 are listed in Table 7 for comparison, comparative example 9 and examples 12-13 were tested for H absorption 2 The ability of S.
TABLE 7 (percentages in the table are by weight)
As can be seen from table 7:
comparative example 9 is a 0.1% strength aqueous solution of Lactobacillus paracasei, H 2 The S reduction rate is only 3%;
example 12 is a method in which 0.1% by mass of Lactobacillus paracasei is added to example 2, and the oral gas-absorbing ability of the solution is determined by 59% 2 S reduction rate was increased to 69% 2 (ii) a rate of S reduction;
example 13 is a case where 2% by mass of Lactobacillus paracasei was added to example 5The capacity of the solution to absorb halitosis is 64% from the original 2 S reduction rate is increased to 82% 2 The S reduction rate and the increase are larger than those of the example 12.
Examples 14 to 16
The oral care compositions were formulated as in Table 8 as examples 14-16; for comparison, examples 14-16 were tested for H absorption as shown in Table 6 for example 2 and example 5 2 The ability of S.
TABLE 8 (percentages in the table are by weight)
As can be seen from table 8:
3# inulin was added to the formulation of example 14 at a concentration of 5%, when H was present 2 The reduction rate of S increased to 94%;
3# inulin was added to the formulation of example 15 at a concentration of 10%, when H was present 2 The reduction rate of S was 95%,
3# inulin was added to the formulation of example 16 at a concentration of 30%, when H was added 2 The reduction rate of S was 97%.
Method for evaluating efficacy of balanced flora
1. Preparing 0.3% culture medium solution and 0.1% cysteine, sterilizing at 121 deg.C for 208in, and cooling to room temperature.
2. Adding reagents according to the following sequence and proportion: medium, cysteine, saliva, sample solution.
3. And covering the sealing bottle with a rubber pad and a cover, and sealing.
After 4.0h and 24h, collecting the metabolite in the bottle for gene sequencing.
5. The PCR was performed on Roche 480Real-Ti8e PCR or ABI 7500 using TaKaRa
Pre8ix Ex TaqTM (TaKaRa Code: DRR 041A) kit instructions.
6. A two-step PCR reaction program is adopted, and the specific program is as follows: two-step PCR amplification standard procedure: reps:1 (95 ℃ for 30 seconds), reps:40 (95 ℃ for 5 seconds, T8 ℃ for h seconds); different extension temperatures and times are determined for different primers.
7. After the reaction, the amplification curve, melting curve, etc. of Real Ti8e PCR were confirmed, and Ct value was calculated.
8. Counting data, and calculating the relative proportion of each bacterium; the results are shown in FIG. 1.
As can be seen from FIG. 1, the concentration of the beneficial bacteria Veillonella parvula, streptococcus sanguinis in the population was significantly increased compared to the control, while the concentration of the pathogenic bacteria Fusobacterium nucleatum, porphyromonas Gingivalis, prevotella oralis, in particular Fusobacterium nucleatum, was decreased.
It should be understood that the above-described embodiments of the present invention are merely examples for clearly illustrating the present invention and are not intended to limit the embodiments of the present invention. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. It is not exhaustive here for all embodiments. All obvious changes and modifications which are obvious to the technical scheme of the invention are covered by the protection scope of the invention.
Claims (15)
1. An oral care composition comprising a film, comprising:
1) Inulin;
2) An orally acceptable carrier;
wherein the inulin contains maltose, and the mass ratio of maltose in the inulin is 0.05-1%;
the inulin accounts for 0.1-30% of the oral care composition by mass.
2. The oral care composition comprising a film according to claim 1, characterized in that: the mass ratio of the maltose in the inulin is 0.1-1%.
3. The oral care composition comprising a film according to claim 2, characterized in that: the mass ratio of the maltose in the inulin is 0.39-1%.
4. The oral care composition comprising a film according to claim 1, characterized in that: the inulin accounts for 5-30% of the weight of the oral care composition.
5. The oral care composition comprising a film according to claim 1, characterized in that: the oral care product further comprises a soluble zinc salt.
6. The oral care composition comprising a film according to claim 5, characterized in that: the soluble zinc salt is selected from one or more of zinc citrate, zinc sulfate, zinc nitrate, zinc chloride and zinc gluconate.
7. The oral care composition comprising a film according to claim 6, characterized in that: the soluble zinc salt is zinc citrate.
8. The oral care composition comprising a film according to claim 5, characterized in that: the mass ratio of the soluble zinc salt in the composition is 0.01-2.2%.
9. The oral care composition comprising a film according to claim 5, characterized in that: the inulin: the mass ratio of the soluble zinc salt is 25-1:4.
10. The oral care composition comprising a film according to claim 9, characterized in that: the inulin: the mass ratio of the soluble zinc salt is 10-5:8.
11. The oral care composition comprising a film according to claim 1, characterized in that: the oral care composition further comprises lactobacillus paracasei.
12. The oral care composition comprising a film according to claim 1, characterized in that: the oral care composition further comprises xylitol.
13. The oral care composition comprising a film according to claim 1, characterized in that: the oral care composition is a mouthwash or a liquid toothpaste.
14. Use of an oral care composition according to any one of claims 1 to 12 for absorbing breath.
15. Use of an oral care composition according to any one of claims 1 to 12 for inhibiting the growth of oral harmful bacteria and promoting the growth of oral beneficial bacteria.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110810685.6A CN115624506B (en) | 2021-07-16 | 2021-07-16 | Oral care composition containing inulin and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110810685.6A CN115624506B (en) | 2021-07-16 | 2021-07-16 | Oral care composition containing inulin and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115624506A true CN115624506A (en) | 2023-01-20 |
| CN115624506B CN115624506B (en) | 2024-06-18 |
Family
ID=84902242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110810685.6A Active CN115624506B (en) | 2021-07-16 | 2021-07-16 | Oral care composition containing inulin and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115624506B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6280769B1 (en) * | 1999-09-13 | 2001-08-28 | Nabisco, Inc. | Breath freshening comestible product |
| US20130089506A1 (en) * | 2010-06-24 | 2013-04-11 | Colgate-Palmolive Company | Oral care compositions and methods |
| CN104920772A (en) * | 2015-05-27 | 2015-09-23 | 闭炳春 | Tooth decay preventing chewing gum and a preparation method thereof |
| CN106821950A (en) * | 2017-01-23 | 2017-06-13 | 衡阳美娇七商贸有限公司 | The oral care composition and its application of a kind of antibacterial and whitening |
| US20210177724A1 (en) * | 2019-12-16 | 2021-06-17 | Colgate-Palmolive Company | Oral Care Compositions |
| CN113081893A (en) * | 2021-04-20 | 2021-07-09 | 苏州清馨健康科技有限公司 | Oral bacteriostatic composition, preparation method and application thereof |
-
2021
- 2021-07-16 CN CN202110810685.6A patent/CN115624506B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6280769B1 (en) * | 1999-09-13 | 2001-08-28 | Nabisco, Inc. | Breath freshening comestible product |
| US20130089506A1 (en) * | 2010-06-24 | 2013-04-11 | Colgate-Palmolive Company | Oral care compositions and methods |
| CN104920772A (en) * | 2015-05-27 | 2015-09-23 | 闭炳春 | Tooth decay preventing chewing gum and a preparation method thereof |
| CN106821950A (en) * | 2017-01-23 | 2017-06-13 | 衡阳美娇七商贸有限公司 | The oral care composition and its application of a kind of antibacterial and whitening |
| US20210177724A1 (en) * | 2019-12-16 | 2021-06-17 | Colgate-Palmolive Company | Oral Care Compositions |
| CN113081893A (en) * | 2021-04-20 | 2021-07-09 | 苏州清馨健康科技有限公司 | Oral bacteriostatic composition, preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115624506B (en) | 2024-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105534875B (en) | Antibacterial antiallergic perception compositions and its toothpaste and preparation method for oral-cavity article | |
| CN107998036A (en) | A kind of toothpaste and its manufacture method for oral cavity synthtic price index | |
| Könöonen et al. | Are certain oral pathogens part of normal oral flora in denture‐wearing edentulous subjects? | |
| CN106562923B (en) | Oral care composition containing profitable probliotics and its application in toothpaste | |
| AU2020408410B2 (en) | Oral care compositions containing inulin | |
| Atac et al. | Antibacterial activity of fifth-generation dentin bonding systems | |
| Pham et al. | Efficacy of chlorine dioxide mouthwash in reducing oral malodor: A 2‐week randomized, double‐blind, crossover study | |
| CN111329875A (en) | Oral care composition for repairing oral soft tissue cells and application | |
| CN112826789A (en) | Anti-caries and antibacterial toothpaste containing probiotics and preparation method thereof | |
| Midda et al. | Clinical uses of an enzyme‐containing dentifrice | |
| Eskandarian et al. | Comparison of antimicrobial effects of titanium tetrafluoride, chlorhexidine, xylitol and sodium fluoride on streptococcus mutans: an in-vitro study | |
| Sims | The interpretation and use of Snyder tests and lactobacillus counts | |
| Collaert et al. | Rinsing with delmopinol 0.2% and chlorhexidine 0.2%: short‐term effect on salivary microbiology, plaque, and gingivitis | |
| CN112426376B (en) | Mouthwash and preparation method thereof | |
| WO2007055372A1 (en) | Composition for oral use | |
| CN115624506A (en) | Oral care product containing inulin and application thereof | |
| Goulet et al. | Salivary glucose clearance after rinsing with solutions of different concentrations of glucose | |
| Tanaka et al. | Aluminum concentrations in human deciduous enamel and dentin related to dental caries | |
| CN113101243B (en) | Oral soft tissue cell repair promoter, oral care composition and application | |
| Salehi et al. | Antimicrobial Effect of Kids Dentifrices on Streptococcus mutans and Lactobacillus acidophilus: An In-Vitro Study | |
| CN113288856A (en) | A toothpaste for preventing and treating dental caries and periodontitis and eliminating oral odor | |
| Luoma et al. | Protection by F, I, Sr, and combinations against fermentation attack by Streptococcus sobrinus artificial plaque on bovine enamel | |
| JPS5811927B2 (en) | Oral composition | |
| JPH0717839A (en) | Composition for oral cavity application | |
| Anchidic et al. | EARLY CARIES IN CHILDREN: ETIOLOGY, DIAGNOSIS AND TREATMENT. A NARRATIVE REVIEW. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |